27,907 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 27,907 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,298,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Bank of America Corp DE grew its position in Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after buying an additional 193,479 shares during the period. Mystic Asset Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at approximately $1,181,000. BlackRock Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at approximately $434,871,000. Allworth Financial LP purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $2,357,000. Finally, Rice Hall James & Associates LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $22,800,000.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $43.53 on Friday. The firm’s 50-day moving average is $46.69 and its two-hundred day moving average is $48.41. The company has a market capitalization of $2.53 billion, a PE ratio of -22.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 12-month low of $42.45 and a 12-month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. During the same period last year, the business earned $0.40 earnings per share. The company’s revenue for the quarter was up 32.4% on a year-over-year basis. On average, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Analyst Ratings Changes

SUPN has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.